JP2024506329A5 - - Google Patents

Info

Publication number
JP2024506329A5
JP2024506329A5 JP2023547848A JP2023547848A JP2024506329A5 JP 2024506329 A5 JP2024506329 A5 JP 2024506329A5 JP 2023547848 A JP2023547848 A JP 2023547848A JP 2023547848 A JP2023547848 A JP 2023547848A JP 2024506329 A5 JP2024506329 A5 JP 2024506329A5
Authority
JP
Japan
Prior art keywords
caution
heterocycloalkyl
cycloalkyl
alkyl
alkenil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023547848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506329A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/015874 external-priority patent/WO2022173870A1/en
Publication of JP2024506329A publication Critical patent/JP2024506329A/ja
Publication of JP2024506329A5 publication Critical patent/JP2024506329A5/ja
Withdrawn legal-status Critical Current

Links

JP2023547848A 2021-02-09 2022-02-09 複素環式化合物およびその使用 Withdrawn JP2024506329A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163147713P 2021-02-09 2021-02-09
US202163147712P 2021-02-09 2021-02-09
US63/147,712 2021-02-09
US63/147,713 2021-02-09
US202163166224P 2021-03-25 2021-03-25
US63/166,224 2021-03-25
US202163176866P 2021-04-19 2021-04-19
US63/176,866 2021-04-19
US202163191910P 2021-05-21 2021-05-21
US63/191,910 2021-05-21
PCT/US2022/015874 WO2022173870A1 (en) 2021-02-09 2022-02-09 Heterocyclic compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2024506329A JP2024506329A (ja) 2024-02-13
JP2024506329A5 true JP2024506329A5 (cg-RX-API-DMAC7.html) 2025-02-19

Family

ID=82837902

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547848A Withdrawn JP2024506329A (ja) 2021-02-09 2022-02-09 複素環式化合物およびその使用

Country Status (6)

Country Link
US (1) US20240254129A1 (cg-RX-API-DMAC7.html)
EP (1) EP4291199A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506329A (cg-RX-API-DMAC7.html)
AU (1) AU2022220678A1 (cg-RX-API-DMAC7.html)
CA (1) CA3207854A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022173870A1 (cg-RX-API-DMAC7.html)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
MD4051678T2 (en) 2019-10-28 2026-07-31 Merck Sharp & Dohme Llc Small molecule inhibitors of the KRAS G12C mutant
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
CA3191279A1 (en) 2020-08-28 2022-03-03 Yi Liu Heterocyclic compounds and uses thereof
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
WO2022135470A1 (zh) * 2020-12-22 2022-06-30 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
WO2022192790A1 (en) * 2021-03-12 2022-09-15 Bristol-Myers Squibb Company Kras inhibitors
CN115141215B (zh) * 2021-03-30 2023-09-15 上海德琪医药科技有限公司 Kras g12d蛋白抑制剂和其用途
EP4329888A1 (en) * 2021-04-29 2024-03-06 Amgen Inc. 2-aminobenzothiazole compounds and methods of use thereof
WO2022232331A1 (en) * 2021-04-29 2022-11-03 Amgen Inc. Heterocyclic compounds and methods of use
AU2022281749A1 (en) * 2021-05-24 2023-11-30 280 Bio, Inc. Nitrogen-containing heterocyclic compound, method for preparing same and use of same
WO2023284881A1 (en) * 2021-07-16 2023-01-19 Silexon Ai Technology Co., Ltd. Heterocyclic compounds useful as kras g12d inhibitors
JP2024532735A (ja) * 2021-08-10 2024-09-10 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法
WO2023020519A1 (en) * 2021-08-18 2023-02-23 Jacobio Pharmaceuticals Co., Ltd. 1, 4-oxazepane derivatives and uses thereof
WO2023039240A1 (en) * 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023061294A1 (zh) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
WO2023072188A1 (zh) * 2021-10-29 2023-05-04 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
US20260200925A1 (en) * 2021-11-24 2026-07-16 Merck Sharp & Dohme Llc Small molecule inhibitors of kras mutated proteins
EP4405337A4 (en) * 2021-11-30 2025-11-26 Beta Pharma Inc Fused pyrimidine derivatives as kras oncoprotein inhibitors
WO2023114733A1 (en) * 2021-12-13 2023-06-22 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2023137223A1 (en) * 2022-01-17 2023-07-20 Newave Pharmaceutical Inc. Pan-kras inhibitors and uses thereof
WO2023138583A1 (zh) * 2022-01-21 2023-07-27 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
IL314486A (en) * 2022-02-03 2024-09-01 Mirati Therapeutics Inc Quinazoline compounds inhibit PAN-KRAS
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
JP2025508702A (ja) * 2022-02-16 2025-04-10 アムジエン・インコーポレーテツド キナゾリン化合物、及び変異krasタンパク質の阻害剤としてのその使用
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023172737A1 (en) 2022-03-11 2023-09-14 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
JP2025510656A (ja) * 2022-03-24 2025-04-15 ベイジーン スウィッツァーランド ゲーエムベーハー 複素環式化合物、その組成物、及びそれらを用いた治療方法
US20240109918A1 (en) * 2022-05-04 2024-04-04 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN117327102B (zh) * 2022-06-30 2026-04-28 重庆华森英诺生物科技有限公司 Kras抑制剂、其制备方法及应用
WO2024008068A1 (en) * 2022-07-04 2024-01-11 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024008179A1 (en) * 2022-07-07 2024-01-11 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
TW202426451A (zh) * 2022-08-24 2024-07-01 大陸商泰勵生物科技(上海)有限公司 具有抗kras突變腫瘤活性的化合物
EP4577214A2 (en) * 2022-08-26 2025-07-02 Merck Sharp & Dohme LLC Small molecule inhibitors of kras proteins
WO2024045066A1 (en) * 2022-08-31 2024-03-07 Nikang Therapeutics, Inc. Alkylidene carbamate as kras inhibitors
WO2024054926A1 (en) * 2022-09-07 2024-03-14 Bristol-Myers Squibb Company Kras g12d inhibitors
WO2024054625A2 (en) * 2022-09-08 2024-03-14 Nikang Therapeutics, Inc. Bifunctional compounds for degrading kras g12d via ubiquitin proteasome pathway
WO2024056063A1 (zh) * 2022-09-16 2024-03-21 南京明德新药研发有限公司 含六氢螺环[环丙烷-1,2'-吡咯嗪]的化合物
WO2024061365A1 (zh) * 2022-09-22 2024-03-28 成都奥睿药业有限公司 嘧啶并环类化合物及其制备方法与用途
WO2024063576A1 (ko) * 2022-09-23 2024-03-28 일동제약(주) Kras 저해 물질로서 신규한 퀴나졸린 화합물
CN117917416A (zh) 2022-10-21 2024-04-23 上海领泰生物医药科技有限公司 Kras g12d降解剂及其制备方法和应用
EP4631942A1 (en) 2022-10-21 2025-10-15 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. Pan-kras degrading agent, and preparation method therefor and use thereof
KR20250109197A (ko) 2022-11-21 2025-07-16 트리라인 바이오사이언시스, 인크. 스피로환식 디하이드로피라노피리미딘 KRas 억제제
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
CN118772151A (zh) * 2023-04-04 2024-10-15 泰励生物科技(上海)有限公司 具有抗kras突变肿瘤活性的化合物
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2024238633A2 (en) * 2023-05-15 2024-11-21 Mirati Therapeutics, Inc. Kras g12s and g12c inhibitors
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
EP4735451A1 (en) 2023-06-30 2026-05-06 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
WO2025019823A1 (en) * 2023-07-20 2025-01-23 Merck Sharp & Dohme Llc Small molecule protein degraders of kras g12d mutant
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
KR20260054710A (ko) 2023-08-17 2026-04-22 트리라인 바이오사이언시스, 인크. 스피로시클릭 디히드로피라노피리미딘 KRas 저해제
AU2024337016A1 (en) * 2023-09-08 2026-04-16 Tyligand Bioscience (Shanghai) Limited Ras inhibitor
WO2025064848A1 (en) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
KR20260084633A (ko) 2023-10-10 2026-06-05 청두 하이퍼웨이 파마슈티컬스 컴퍼니 리미티드 축합 고리 화합물 및 kras 억제제로서의 응용
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
TW202545934A (zh) * 2024-02-05 2025-12-01 日商安斯泰來製藥股份有限公司 包含具有突變kras蛋白分解誘導作用之雜環化合物的抗體藥物複合體
AU2025218254A1 (en) * 2024-02-06 2026-07-23 Windermere Therapeutics, Inc. Kras(g12d) inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025218811A1 (zh) * 2024-04-19 2025-10-23 领泰生物医药(绍兴)有限公司 pan-KRAS靶向蛋白降解剂及其制备方法和应用
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190186A1 (ar) * 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
WO2020097537A2 (en) * 2018-11-09 2020-05-14 Genentech, Inc. Fused ring compounds
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2022076917A1 (en) * 2020-10-08 2022-04-14 Kumquat Biosciences Inc. Modulators of cell proliferation and uses thereof
US20240417412A1 (en) * 2021-08-10 2024-12-19 Amgen Inc. Heterocyclic compounds and methods of use
EP4389751A1 (en) * 2021-09-03 2024-06-26 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2023540270A5 (cg-RX-API-DMAC7.html)
AU2017263478B2 (en) Combination therapies of HDAC inhibitors and PD-1 inhibitors
KR102356433B1 (ko) 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법
US11730736B2 (en) Anticancer agents
AU2011302344B2 (en) HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
ES2661216T3 (es) Método combinado para tratar el cáncer o un estado precanceroso
EP2786754B1 (en) Combination therapy with a mitotic inhibitor
JP2014132009A5 (cg-RX-API-DMAC7.html)
US20160324829A1 (en) Combination therapy with parp inhibitors
JP2017516775A (ja) がんの処置のための併用治療
JP2012500180A5 (cg-RX-API-DMAC7.html)
EA022119B1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений - ингибиторов hsp90
JP2006503867A (ja) 癌を処置するための相乗的な方法および組成物
ES2408597T3 (es) 1,2,3-triazoles inhibidores de la polimerización de la tubulina para el tratamiento de trastornos proliferativos
CN108136207A (zh) 用于治疗癌症的联合疗法
US20130225647A1 (en) Combination therapy with parp inhibitors
JP2020533292A (ja) コパンリシブの製剤
TR201806682T4 (tr) Farmasötik kombinasyonlar.
RU2016133336A (ru) Новые производные CYP-эйкозаноидов
JP2016501884A5 (cg-RX-API-DMAC7.html)
EP2754441A2 (en) Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
RU2002105518A (ru) Гетероциклические соединения, ингибирующие ангиогенез
CN121218988A (zh) 治疗未接受bcl2抑制剂的受试者的癌症的方法
JP5570429B2 (ja) デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法
CN121398817A (zh) 治疗具有先前免疫检查点抑制剂暴露的受试者的癌症的方法